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Abstract
Background: An association has been observed between the catechol-O-methyltransferase (COMT)
gene, the predominant means of catecholamine catabolism within the prefrontal cortex (PFC), and
neuropsychological task performance in healthy and schizophrenic adults. Since several of the
cognitive functions typically deficient in children with Attention Deficit Hyperactivity Disorder
(ADHD) are mediated by prefrontal dopamine (DA) mechanisms, we investigated the relationship
between a functional polymorphism of the COMT gene and neuropsychological task performance
in these children.
Methods: The Val108/158 Met polymorphism of the COMT gene was genotyped in 118 children with
ADHD (DSM-IV). The Wisconsin Card Sorting Test (WCST), Tower of London (TOL), and Self-
Ordered Pointing Task (SOPT) were employed to evaluate executive functions.
Neuropsychological task performance was compared across genotype groups using analysis of
variance.
Results: ADHD children with the Val/Val, Val/Met and Met/Met genotypes were similar with regard
to demographic and clinical characteristics. No genotype effects were observed for WCST
standardized perseverative error scores [F2,97 = 0.67; p > 0.05], TOL standardized scores [F2,99 =
0.97; p > 0.05], and SOPT error scores [F2,108 = 0.62; p > 0.05].
Conclusions: Contrary to the observed association between WCST performance and the Val108/
158  Met  polymorphism of the COMT  gene in both healthy and schizophrenic adults, this
polymorphism does not appear to modulate executive functions in children with ADHD.
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Background
Attention Deficit Hyperactivity Disorder (ADHD) is a
childhood psychiatric disorder characterized by symp-
toms of inattention, impulsivity and motor hyperactivity
afflicting 6–8% of school-aged children in North America
[1,2]. Although ADHD is a disorder with complex and
heterogeneous etiology, genetic factors appear to play a
significant role in predisposing and perpetuating the
development of the disorder as evidenced by twin [3,4],
family [5-7], and adoption studies [8]. Association studies
have implicated several susceptibility loci including a 40-
base pair (bp) allele of the Variable Number of Tandem
Repeats (VNTR) polymorphism of the SLC6A3 gene [9]
and a 48-bp repeat polymorphism of the DRD4 gene [10].
Attempts to replicate these findings have met with modest
success possibly owing to the clinical heterogeneity char-
acteristic of the disorder [11]. One method that may act to
augment the strength of these associations would be to
identify endophenotypic intermediates conferring risk for
the development of ADHD rather than attempting to
identify direct linkages between genetic variations and the
behavioural manifestation of the disorder.
Theories of dysregulated dopamine (DA) pathways in
ADHD have been supported by the efficacy of dopamine
agonists in reducing the core symptoms of the disorder
[12]. The mesocortical DA pathway appears to be integral
to prefrontal cortex (PFC)-mediated cognitive function-
ing, specifically working memory [13], through the
enhancement of task-related neural activity via D1 recep-
tor activation [14]. Both PET [15] and SPECT [16] imaging
studies support a neuromodulatory role for DA in the PFC
during tasks of executive function. In addition, adminis-
tration of DA agonists to the rat PFC acts to enhance work-
ing memory in these animals [17]. Consistent with this
line of thinking, children with ADHD show deficits in per-
formance of tasks of executive function [summarized in a
meta-analysis by Sergeant et al. (2002)] [18] and signifi-
cant improvement of performance under methylpheni-
date [19,20]. These findings have prompted the
hypothesis that the overt symptoms of ADHD are the
manifestation of an underlying deficiency in a range of
PFC-mediated cognitive domains, including working
memory, planning, and set shifting, collectively regarded
as executive function [21-23].
The hypothesized role of a dysfunctional mesocortical
dopaminergic pathway in the development of symptoms
of ADHD has encouraged the investigation of candidate
genes involved in this pathway including SLC6A3  [9],
DRD4 [10] and, more recently, the catechol-O-methyltrans-
ferase (COMT) gene [24]. The COMT, encoded by a gene
located on chromosome 22q11, catalyzes the degradation
of catecholamines, most importantly DA [25]. A func-
tional polymorphism of this gene, involving a substitu-
tion of Valine (Val) for Methionine (Met) at codon 108/
158 (Val108/158  Met), results in a 4-fold variation in
enzyme activity, with individuals homozygous for either
the Val or Met allele exhibiting either reduced or preserved
levels of DA respectively [26]. Although the dopamine
transporter (DAT) is the predominant means of DA termi-
nation in most dopaminergic neurons [27], considerable
evidence exists to suggest that the DAT may play a reduced
role within the PFC [28-32], where other clearance mech-
anisms may be implicated. Comparison of DA metabolite
levels within discrete brain loci in both rats [33] and mon-
keys [34], as well as the measurement of DA levels in
COMT knock-out mice [35], suggest an important func-
tional role for COMT in the PFC. If COMT is indeed inex-
tricably linked to DA metabolism within the PFC, it is
reasonable to assume that variations in enzyme activity, as
dictated by the Val108/158 Met polymorphism, may modu-
late the performance of tasks of executive functioning in
healthy individuals, as well as individuals with reduced
PFC basal dopamine levels. In support of this assumption,
associations have been reported between the Val108/158
Met polymorphism and performance on the Wisconsin
Card Sorting Test (WCST) in healthy adults [36,37]. In
adults with Schizophrenia, a disorder characterized by
dopaminergic hypofrontality [38], associations have also
been observed between the COMT  polymorphism and
WCST performance [39-41]. Although one study reported
an association between the COMT  polymorphism and
ADHD using a haplotype relative risk design [24], this
study failed to investigate any indices of executive func-
tion and several other studies failed to replicate this find-
ing [3,42-44].
Given the putative role of COMT  in DA metabolism
within the PFC [33-35], we hypothesized that the Val108/
158 Met polymorphism of the COMT gene will be associ-
ated with alterations in performance on tasks of executive
function, a behavioural index of PFC integrity and func-
tion [45]. Since dysfunctional DA neurotransmission [46]
and deficient neuropsychological task performance [18]
are both characteristic of children with ADHD, we further
hypothesized that this association would be evident
within this particular clinical population. Specifically,
ADHD children expressing the high enzymatic activity Val
allele (H), resulting in reduced PFC DA neurotransmis-
sion [26], will show more pronounced deficits in neu-
ropsychological task performance than their low
enzymatic activity Met allele (L) counterparts. In order to
test this hypothesis, we used three measures of executive
function: the WCST [47], a measure of set-shifting ability
capable of differentiating between ADHD children and
controls [18] and associated with the COMT polymor-
phism in normal [36,37] and schizophrenic adults [39-
41]; the Tower of London (TOL) [48], a measure of plan-
ning ability, which consistently differentiates ADHDBMC Medical Genetics 2004, 5:30 http://www.biomedcentral.com/1471-2350/5/30
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children from controls [18], and the Self-Ordered Point-
ing Task (SOPT) [49], a measure of working memory also




118 children were recruited from the Disruptive Behav-
iour Disorders Program and the children outpatient clinic
at the Douglas Hospital. They were referred to these spe-
cialized care facilities by school principals, community
social workers, and paediatricians.
Inclusion criteria required children to be between the ages
of 6 and 12 years of age, meeting DSM-IV diagnosis crite-
ria for ADHD [50]. Diagnosis of ADHD was based on a
structured clinical interview of parents using the DISC-IV
(parental report) [51], school reports, teacher interviews,
and clinical observation of the child. In the majority of
cases, mothers were the primary informants for the collec-
tion of clinical information. Written reports from the
child's school were also available in the majority of cases.
Parents completed the Child Behavioural Checklist
(CBCL) [52], a scale that assesses a variety of behavioural
domains, and the Conners' Global Index for parents
(CGI-P) [53]. Teachers also completed the Conners' Glo-
bal Index (CGI-T) [54]. Assessments were made while
children were free of medication. Exclusion criteria
included a history of mental retardation, with an IQ less
than or equal to 70 as measured by the WISC-III [55], and
history of Tourette Syndrome, pervasive developmental
disorder, psychosis or any medical condition or impair-
ment that may interfere with the child's ability to com-
plete the study.
Neurocognitive assessment
A comprehensive neuropsychological test battery assess-
ing different aspects of the central executive functions was
administered to all children by trained research person-
nel. All children were assessed subsequent to a one-week
medication "wash-out" period. Children were permitted
to take breaks upon request and, in some cases, testing
was carried out over two sessions. On average, the testing
procedure lasted 1.5 hours. The research protocol was
approved by the Research Ethics Board of the Douglas
Hospital. Parents were explained the study and provided
written consent. Children were also explained the study
and gave their assent to participate as well.
Tests were selected according to their ability to tap into
various performance domains of executive function. We
restricted the number of tests in each domain in order to
balance comprehensiveness with the co-operation of
patients. Abstraction and concept formation were evalu-
ated by means of the WCST (perseverative errors) [47]. In
this task, children are required to sort cards according to
three different criteria (colour, number, or shape of signs
presented on cards). Feedback on whether the child
achieved a correct or incorrect match is given after each
trial. The matching criterion changes after ten consecutive
correct matches and the child has to identify the new
matching criterion using the feedback (correct/incorrect)
provided to them. Evidence of the reliability and validity
of the WCST with various normal and clinical populations
has been reported in several studies [18]. Planning capac-
ity was evaluated using the TOL [48]. This test is used to
assess planning and problem solving aspects of executive
functioning. The validity and reliability of the TOL has
been reported in numerous studies [18]. Standardized
administration and scoring procedures as well as norma-
tive data have been developed for paediatric populations
[56]. Visual Working Memory was evaluated using the
abstract version of the SOPT [49]. In this task, series of
matrices of 6, 8, 10, and 12 images are presented to the
child. The child is asked to select, by pointing, one differ-
ent image on each page. Errors occur when the child
points to images previously selected on the preceding
pages. Each set is presented to the child three times. Suc-
cessful performance on this task involves working mem-
ory as well as planning and monitoring skills. Shue &
Douglas (1992) have reported significant differences in
performance between ADHD children and normal con-
trols on the SOPT [57].
Molecular genetics
The Val108/158 Met polymorphism of the COMT gene was
genotyped using a PCR based method as previously
described [26]. The PCR was performed in a 25 µl total
reaction volume containing 1X PCR buffer, 200 uM
dNTPs, 200 ng of primers (5'-GCGATGGTGGCACTC-
CAAGC; 5'-TTGGAGAGGCTGAGGCTGAC), 1 unit of Taq
DNA polymerase, and 100 ng of genomic DNA. PCR
products were electrophoresed on agarose-TAE gel along
with 1 kb ad 100 bp DNA ladders, visualized under UV-
light and coded according to the length of the PCR prod-
uct. Genotypes were called by two independent and expe-
rienced technicians who were blind to all clinical data. No
disconcordance in any of the readings was noted. Chil-
dren were stratified according to genotype only after all
neuropsychological task data was collected.
Statistical analyses
The  Val108/158 Met  polymorphism consists of both the
low-activity Met (L) and high-activity Val (H) alleles. Sub-
jects were stratified into three groups: two homozygous
genotype groups (LL, HH) and one heterozygous geno-
type group (HL).
A one-way analysis of variance (ANOVA) where genotype
(LL, HL, HH) was the independent variable andBMC Medical Genetics 2004, 5:30 http://www.biomedcentral.com/1471-2350/5/30
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neuropsychological task performance (standardized
WCST perseverative error score, standardized TOL total
item score) was the dependent variable was performed.
For the SOPT, no normalized scores are available and test-
ing procedures involve several levels of difficulty (4). We
therefore used a two-way, repeated measure, mixed design
analysis of covariance (ANCOVA), where genotype and
level of task difficulty were the between and within sub-
jects independent variables, respectively, neuropsycholog-
ical task performance (SOPT raw error score) was the
dependent variable, and age was the covariate. As the TOL
also involves multiple levels of task difficulty (12), we
repeated the analysis for this test using the same statistical
approach as that applied to the SOPT. A one-way
ANCOVA, where genotype was the independent variable
and age was the covariate, was performed on all other
non-standardized measures of neuropsychological task
performance (WCST number of categories completed,
WCST number of trials to first category, TOL number of
problems solved).
An investigation of linkage and within-family association
between quantitative phenotypes (standardized WCST
perseverative error score, standardized TOL error score,
and SOPT error score) was conducted utilizing the Quan-
titative Trait Disequilibrium Test (QTDT) statistical soft-
ware package [58].
Results
Table 1 shows clinical and demographic information for
the children stratified according to genotype [n = 23 for LL
(19.5%), n = 66 for HL (56.0%) and n = 29 for HH
(24.5%)]. The three groups were similar with regard to
age, average household income, severity of behavioural
problems as assessed by the CBCL, and mean number of
inattention items, mean number of hyperactivity items
and distribution of ADHD subtypes according to the
DISC-IV. No significant differences existed between the
groups in IQ as measured by the WISC-III. Our sample
was characterized by a high prevalence of comorbid disor-
ders, particularly oppositional defiant disorder and con-
duct disorder. The frequency of these disorders was
equally distributed between the genotype groups. The
proportion of subjects who had never received medica-
tion for ADHD within each genotype group was also
remarkably similar. Although a significant effect of gender
was observed between genotype groups (χ2 = 7.39; df = 2,
p = 0.02), this result was treated as a type I error (false pos-
itive) due to the absence of female subjects with the HH
genotype and given the relative lack of female representa-
tion across all genotype groups. However, given the previ-
ously observed association between gender and several
polymorphisms at the COMT  loci [59], increasing the
sample size to achieve a more comparable gender repre-
sentation and distribution would be a valuable revision to
the present design.
The genotype distribution conformed to a Hardy-Wein-
berg equilibrium (χ2 = 0.42; df = 2, p = 0.81). 156 parents
participated in the study and gave blood samples. Among
these parents, 76 were heterozygous (M = 43 and F = 33)
and transmitted the Val allele to their affected children in
28 occurrences, whereas this same allele was not transmit-
ted in 29 occurrences [χ2 = 0.02; df = 1, p > 0.05 (transmis-
sion disequilibrium)]. Conversely, parents transmitted
the Met allele to their affected children in 29 occurrences,
whereas this same allele was not transmitted in 28 occur-
rences [χ2 = 0.02; df = 1, p > 0.05 (transmission disequi-
librium)]. In addition, results from the QTDT revealed no
evidence of linkage or within-family association between
the three quantitative phenotypes and the COMT gene.
A one-way ANOVA performed on these data revealed no
significant difference between the LL, HL, and HH geno-
Table 1: Demographic and clinical characteristics of children with ADHD separated according to COMT genotype
LL (23) HL (66) HH (29) p-value
Gender (M/F) 20/3 52/14 29/0 χ2 = 7.39, df = 2 p = 0.02
Age 9.2 (2.0) 9.0 (1.8) 9.3 (1.7) F2,115 = 0.21, p = 0.81
IQ 97.2 (13.7) 97.5 (13.5) 95.6 (13.8) F2,98 = 0.17, p = 0.84
CBCL (total score) 68.0 (9.8) 70.9 (10.4) 68.9 (8.9) F2,112 = 0.87, p = 0.42
Income (% less than 20 K) 32 % 42 % 48 % χ2 = 1.39, df = 2 p = 0.50
DISC-IV Inattention Items 7.3 (1.5) 6.9 (2.2) 7.2 (2.3) F2,113 = 0.46, p = 0.63
DISC-IV Hyperactivity Items 5.9 (2.4) 6.4 (2.3) 6.4 (2.7) F2,113 = 0.33, p = 0.72
DISC-IV ADHD Subtype (I/H/C) 10/3/10 14/13/39 7/3/19 χ2 = 5.68, df = 2 p = 0.22
Comorbid ODD 13/23 50/66 20/27 χ2 = 3.21, df = 2 p = 0.20
Comorbid CD 5/23 27/64 8/27 χ2 = 3.57, df = 2 p = 0.17
Never Medicated 11/22 38/62 18/28 χ2 = 1.17, df = 2 p = 0.56
CBCL = Child Behavioral Checklist. DISC-IV = Diagnostic Interview Schedule for Children fourth edition. ODD = Opposition Defiant Disorder, 
CD = Conduct Disorder. ADHD Subtypes: I = Inattentive, H = Hyperactive, C = Combined. Values are mean (SD).BMC Medical Genetics 2004, 5:30 http://www.biomedcentral.com/1471-2350/5/30
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types according to WCST standardized perseverative error
scores [F2,97 = 0.66, p > 0.05](Table 2) and TOL standard-
ized total item scores [F2,99 = 0.97, p > 0.05](Table 2). A
repeated-measure, mixed design ANCOVA performed on
these data revealed no effect of genotype on SOPT raw
error scores [F2,108 = 0.62, p > 0.05] (Table 2), TOL raw
item scores [F2,107 = 0.35, p > 0.05], and TOL time to com-
plete each trial [F2,108 = 0.04, p > 0.05]. No genotype by
task interaction was observed for SOPT raw error scores
[F6,327 = 0.39, p > 0.05], TOL raw item scores [F11,1199 =
1.63, p > 0.05], and TOL time to complete each trial
[F11,1210 = 1.65, p > 0.05]. A one-way ANCOVA performed
on these data revealed no effect of genotype on WCST
number of categories completed [F2,96 = 1.94, p > 0.05],
WCST number of trials to first category [F2,96 = 1.04, p >
0.05] and TOL number of problems solved [F2,112 = 1.04,
p > 0.05]. No genotype effects were observed when the HL
and HH genotype groups were combined into one cate-
gory and contrasted with the LL genotype (recessive
model) on WCST standardized perseverative error scores
[F1,98 = 1.11, p > 0.05], WCST number of categories com-
pleted [F1,97 = 0.01, p > 0.05], WCST number of trials to
first category [F1,97 = 0.36, p > 0.05], TOL standardized
total item scores [F1,100 = 0.42, p > 0.05], TOL raw item
scores [F1,108 = 0.22, p > 0.05], TOL time to complete each
trial [F1,109 = 0.07, p > 0.05], TOL number of problems
solved [F1,113= 1.33, p > 0.05] and SOPT raw error scores
[F1,109 = 0.85, p > 0.05].
Discussion
Previous studies have identified an association between
the COMT polymorphism and a variety of indices reflect-
ing executive control both in healthy [36,37] and schizo-
phrenic adults [39-41]. The COMT  appears to be
important to the regulation of dopamine metabolism
within the PFC [33-35]. Since the PFC and dopamine
pathways have been hypothesized to play an important
role in the pathogenesis of ADHD [9-11,60,61]), we con-
ducted this study in an attempt to test whether the COMT
Val108/158Met polymorphism, which is known to be asso-
ciated with a significant change in the catabolic capacity of
this enzyme, modulates the risk for ADHD or various
indices of executive control. Contrary to our expectations
and findings in both healthy [36,37] and schizophrenic
adults [39-41], an association between the Val108/158 Met
functional polymorphism of the COMT gene and neu-
ropsychological task performance reflecting executive
control was not observed in children with ADHD. This
result is consistent with the findings of a recent case-con-
trol study conducted by Mills et al. (2004), which, to our
knowledge, is the only other study to investigate the rela-
tionship between the COMT Val108/158Met polymorphism
and neuropsychological task performance in children
with ADHD [62]. However, this study did not include the
WCST, the measure responsible for producing the most
consistent results in the previous literature. In addition,
we did not identify a biased transmission of either of the
two alleles from parents to affected offspring.
The absence of an association between the COMT Val108/
158Met polymorphism and behavioral indices of executive
function in children with ADHD may be explained by the
young age of the population of patients included in the
present study. Indeed it is possible that, due to age-related
changes in the functional importance of the COMT within
the prefrontal cortex, this association is observable only in
adults. This possibility is supported by data in both rats
[63-65] and humans [66,67] suggesting that monoamine
content and metabolism decrease with age. This age-
related decrease may render functions dependent on
monoamine content more prone to be dysfunctional at an
older age. In addition, evidence from rat studies has indi-
cated a positive correlation between aging and COMT
activity [68-70]. This observation may suggest that the
implication of the COMT in the catabolism of dopamine
is developmentally regulated, with children relying less on
this catabolic pathway than adults. Conversely, it has
been reported that DAT density is inversely correlated
with age [71]. Taken together, the presence of an inverse
and direct correlation between age and DAT density on
the one hand and COMT activity on the other hand, may
suggest that dopamine metabolism relies more on the
DAT than on COMT  activity in children compared to
adults. This hypothesis is compatible with the fact that
several studies have identified an association between the
DAT [9,60,72-74], but not the COMT, gene and ADHD.
Table 2: Neuropsychological task performance in children with ADHD
LL (23) HL (66) HH (29) ES p-value
WCST 96.3 (15.1) 99.1 (11.8) 100.6 (12.2) 0.31 F2,97 = 0.67, p = 0.52
TOL 103.3 (16.5) 99.5 (15.1) 103.8 (12.6) 0.03 F2,99 = 0.97, p = 0.38
SOPT 13.5 (6.9) 15.1 (8.8) 15.8 (8.2) 0.31 F2,108 = 0.62, p = 0.54
WCST = Wisconsin Card Sorting Test standardized perseverative error score (LL: n = 21, HL: n = 56, HH: n = 23). TOL = Tower of London 
standardized score (LL: n = 20, HL: n = 55, HH: n = 27). SOPT = Self Ordered Pointing Task error score (LL: n = 23, HL: n = 63, HH: n = 26). ES = 
Effect size for LL vs. HH. Values are mean (SD).BMC Medical Genetics 2004, 5:30 http://www.biomedcentral.com/1471-2350/5/30
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It is also possible that the negative result observed in the
present study is due to a type II error (false negative) sec-
ondary to the lack of power of our sample to detect an
association. However, using results from the WCST, the
variable for which relevant genetic data already exists, we
conducted a power analysis and determined that our sam-
ple size has sufficient power (80% at α = .05) to detect a
mean difference of 11.2 on this measure. Furthermore, it
is possible that some of the tests used in our assessment
are mediated by the PFC but insensitive to PFC DA levels
[75].
An additional limitation of the present study is that some
genotype groups included few subjects. Increasing the
sample size to achieve larger genotype groups would be
necessary to reach firmer conclusions. This is particularly
true for female subjects who were significantly underrep-
resented in the study (as is common to most clinical stud-
ies of ADHD). In order to generalize these negative results
to females, a more comparable gender representation is
required, particularly in view of some previous research
indicating that the allelic distribution of the COMT may
be gender dependent [59].
Conclusions
This study does not support the involvement of the Val108/
158 Met polymorphism of the COMT gene in increasing the
risk for ADHD or in modulating several indices of execu-
tive functions in children with ADHD. This result is con-
trary to previous findings in both healthy and
schizophrenic adults and may be related to developmen-
tal specificities.
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